Prof. Patricio Sepulveda is an entrepreneur, scientist, and research commercialization Executive. He founded Bravo Biotech a pre-clinical AAV company for ALS and the MHx, an early stage health-technology accelerator.
Patricio's experience includes Directing the technology transfer office of the Royal Melbourne Hospital, Senior Manager in M&A and Licensing at CSL Behring, managing global research projects for the Movember Foundation, CSO at Myostin Therapeutics, working as an analyst at the Venture Capital firm Brandon Capital Partners and guest scientist at the Department of Neurophysiology of Uppsala University.
An adviser to Save Our Sons Duchenne Australia, Duchenne Alliance US, PNET Cancer Foundation, and private consultant to Milo Biotechnology. He conducted his Ph.D. in AAV Gene Therapy at the Baker Research Institute and has an Executive MBA from the Melbourne Business School at the University of Melbourne.
Sign up to view 2 direct reports
Get started